Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS) for adult patients with recurrent, platinum sensitive,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Invest New Drugs
Glavni autori: van Andel, Lotte, Zhang, Z., Lu, S., Kansra, V., Agarwal, S., Hughes, L., Tibben, M. M., Gebretensae, A., Lucas, L., Hillebrand, M. J. X., Rosing, H., Schellens, J. H. M., Beijnen, J. H.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2017
Teme:
Phase I Studies
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694528/
https://ncbi.nlm.nih.gov/pubmed/28303528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0451-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items